Technology ID
TAB-3702
Five Human Embryonic Stem Cell (hESC) Lines with Reporters for Stem Cell Biology Research
E-Numbers
E-095-2013-0
Lead Inventor
Park, KyeYoon (National Institute of Neurological Disorders and Stroke)
Co-Inventors
Rao, Mahendra (NIAMS)
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NINDS
ICs
NIAMS
This technology includes the creation and use of five human embryonic stem cell (hESC) lines with reporter genes integrated at safe harbor sites. These cell lines can be used to study the biology of stem cell development, including their use as an assay for small molecules.
The reporter genes and integration sites are listed below:
The reporter genes and integration sites are listed below:
- EEF1A1p-ZsGreen-2A-Puro at the AAVS1 safe harbor site
- DCXp-ZsGreen-2A-Puro/PGKp-Hygro at the AAVS1 safe harbor site
- TNNT2p-ZsGreen-2A-Puro/PGKp-Hygro at the AAVS1 safe harbor site
- RPE65p-ZsGreen-2A-Puro/PGKp-Hygro at the AAVS1 safe harbor site
- PDX1p-ZsGreen-2A-Puro/PGKp-Hygro at the AAVS1 safe harbor site
Commercial Applications
These cell lines will be used for to study the biology of stem cell development and may also be used to test different characterization and differentiation assays. These cell lines may also be used as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases. As these cells have the capacity to differentiate into all cell types in the body and have an infinite capacity to self-renew, there is a large range of projects in which these cells could be utilized.
Competitive Advantages
It was our intention to make these lines available to use as control lines and without restrictions on their use in both non- and for-profit entities. It is very expensive for independent investigators or corporations to develop these cell lines, which is why it is important that NIH makes them commercially available. These cells will significantly reduce the financial burden of initiating many research projects.
Licensing Contact: